Introduction
In cardiology practice, managing Acute Coronary Syndrome (ACS) does not end after PCI or thrombolysis. One of the most important long-term decisions is the appropriate use of Dual Antiplatelet Therapy (DAPT).
As clinical pharmacists, we are directly involved in:
- Reviewing discharge medications
- Assessing bleeding risk
- Optimizing therapy duration
- Preventing drug-related complications
- Educating patients before discharge
This article provides a practical and hospital-focused guide to DAPT.
What is Dual Antiplatelet Therapy (DAPT)?
DAPT consists of:
- Aspirin (usually lifelong unless contraindicated)
A P2Y12 inhibitor:
DAPT is standard therapy after:
- ST-elevation myocardial infarction (STEMI)
- Non-ST elevation MI (NSTEMI)
- Unstable angina
- Post-percutaneous coronary intervention (PCI) with stent placement
Choosing the Right P2Y12 Inhibitor
1️⃣ Clopidogrel
- Less potent
- Lower bleeding risk compared to newer agents
- Preferred in high bleeding risk patients
- Once daily dosing
2️⃣ Ticagrelor
- More potent platelet inhibition
- Preferred in ACS when no contraindication
- Twice daily dosing
- Common adverse effect: dyspnea
3️⃣ Prasugrel
- Highly potent
- Age ≥75 years
- History of stroke/TIA
- Weight <60 kg
In many hospital settings, Ticagrelor is preferred in younger ACS patients without significant bleeding risk.
Recommended Duration of DAPT
Standard Recommendation:
12 months after ACS (if no high bleeding risk)
However, duration must be individualized.
Shorter Duration (3–6 months)
Consider in:
- High bleeding risk
- History of GI bleed
- Concomitant anticoagulant use
- Severe anemia
Extended Duration (>12 months)
Consider in:
- Recurrent ischemic events
- Complex PCI
- High ischemic risk with low bleeding risk
As pharmacists, our role is to question whether continuation beyond 12 months is justified.
Assessing Bleeding Risk
Before finalizing therapy duration, evaluate:
- Age
- Renal function
- History of GI bleeding
- Concurrent anticoagulants
- Hemoglobin levels
- Concomitant NSAIDs or steroids
Gastroprotection
High GI risk patients should receive a PPI.
Prefer Pantoprazole if using Clopidogrel to minimize CYP2C19 interaction concerns.
DAPT with Anticoagulants (Triple Therapy)
In patients with:
Triple therapy (Aspirin + P2Y12 inhibitor + DOAC) may be required temporarily.
Current approach:
- Short duration triple therapy (1 week to 1 month)
- Then discontinue aspirin
- Continue DOAC + single antiplatelet
Bleeding risk increases significantly in triple therapy. Close monitoring is essential.
Clinical Pharmacist Monitoring Checklist
✔ Monitor hemoglobin periodically
✔ Assess for occult GI bleeding
✔ Educate patient about bleeding symptoms
✔ Check adherence (especially Ticagrelor BID dosing)
✔ Review drug interactions
✔ Ensure documented stop date in discharge summary
Common medication error:
Failure to specify DAPT duration at discharge.
When to Discontinue DAPT Early?
Possible reasons include:
- Major bleeding event
- Urgent surgery
- Severe thrombocytopenia
Important:
Never discontinue without cardiology consultation due to risk of stent thrombosis.
Conclusion
Dual Antiplatelet Therapy is not simply about combining two drugs. It is about balancing:
Ischemic protection versus bleeding risk.
Clinical pharmacists add value by:
- Individualizing therapy
- Monitoring safety
- Preventing duplication
- Educating patients
- Ensuring proper duration
Appropriate DAPT management significantly reduces recurrent cardiovascular events while minimizing bleeding complications.
References
-
Collet JP, Thiele H, Barbato E, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023.
-
Levine GN, Bates ER, Bittl JA, et al. ACC/AHA Guideline Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Journal of the American College of Cardiology. 2016 (updated recommendations applied in current practice).
-
Mehran R, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 2011.
-
Valgimigli M, et al. Dual Antiplatelet Therapy after PCI: Current Concepts and Future Directions. European Heart Journal. 2022.
 After Acute Coronary Syndrome – Duration, Drug Choice & Monitoring Guide (2026)){kind=link}
0 Comments